癌症进展
癌癥進展
암증진전
ONCOLOGY PROGRESS
2015年
3期
338-341,345
,共5页
早期宫颈癌%炎性标志物%预后
早期宮頸癌%炎性標誌物%預後
조기궁경암%염성표지물%예후
early-stage cervical carcinoma%inflammation biomarkers%prognosis
目的:探讨早期宫颈癌患者术前炎性标志物与疾病进展和预后的关系。方法根据疾病进展情况,将68例接受手术治疗的早期宫颈癌患者分为疾病稳定(stable disease,SD)组(n=56)和疾病进展(progres-sive disease,PD)组(n=12),比较两组患者术前的C反应蛋白(C-reactive protein,CRP)水平、中性粒细胞与淋巴细胞比率(neutrophil-lymphocyte ratio,NLR)、血小板与淋巴细胞比率(platelet-lymphocyte ratio,PLR),并对具有统计学意义(P<0.05)的指标进行分析,以明确其对疾病无进展生存时间(progression-free survival,PFS)的影响。结果三个炎性指标中仅NLR与疾病进展具有相关性(P<0.05),中位NLR值为3.2(0.25~43.3)。NLR<3.2组患者及NLR≥3.2组患者的中位PFS分别为68个月和43个月,差异具有统计学意义(P=0.015)。结论早期宫颈癌患者的术前NLR升高提示患者的PFS较短,预后较差;术前NLR作为患者的预后指标具有一定的临床意义。
目的:探討早期宮頸癌患者術前炎性標誌物與疾病進展和預後的關繫。方法根據疾病進展情況,將68例接受手術治療的早期宮頸癌患者分為疾病穩定(stable disease,SD)組(n=56)和疾病進展(progres-sive disease,PD)組(n=12),比較兩組患者術前的C反應蛋白(C-reactive protein,CRP)水平、中性粒細胞與淋巴細胞比率(neutrophil-lymphocyte ratio,NLR)、血小闆與淋巴細胞比率(platelet-lymphocyte ratio,PLR),併對具有統計學意義(P<0.05)的指標進行分析,以明確其對疾病無進展生存時間(progression-free survival,PFS)的影響。結果三箇炎性指標中僅NLR與疾病進展具有相關性(P<0.05),中位NLR值為3.2(0.25~43.3)。NLR<3.2組患者及NLR≥3.2組患者的中位PFS分彆為68箇月和43箇月,差異具有統計學意義(P=0.015)。結論早期宮頸癌患者的術前NLR升高提示患者的PFS較短,預後較差;術前NLR作為患者的預後指標具有一定的臨床意義。
목적:탐토조기궁경암환자술전염성표지물여질병진전화예후적관계。방법근거질병진전정황,장68례접수수술치료적조기궁경암환자분위질병은정(stable disease,SD)조(n=56)화질병진전(progres-sive disease,PD)조(n=12),비교량조환자술전적C반응단백(C-reactive protein,CRP)수평、중성립세포여림파세포비솔(neutrophil-lymphocyte ratio,NLR)、혈소판여림파세포비솔(platelet-lymphocyte ratio,PLR),병대구유통계학의의(P<0.05)적지표진행분석,이명학기대질병무진전생존시간(progression-free survival,PFS)적영향。결과삼개염성지표중부NLR여질병진전구유상관성(P<0.05),중위NLR치위3.2(0.25~43.3)。NLR<3.2조환자급NLR≥3.2조환자적중위PFS분별위68개월화43개월,차이구유통계학의의(P=0.015)。결론조기궁경암환자적술전NLR승고제시환자적PFS교단,예후교차;술전NLR작위환자적예후지표구유일정적림상의의。
Objective To study the relation between early-stage cervical carcinoma and pre-operative inflamma-tion biomarkers. Method Sixty-eight patients with early-stage cervical carcinoma, who underwent surgery in our hos-pital, were enrolled and grouped as stable disease group (SD group; n = 56) and progressive disease group (PD group; n = 12) based on individual disease conditions during follow up. The levels of pre-operative CRP (C-reactive protein), ratio of NLR (neutrophil- lymphocyte) and PLR (platelet- lymphocyte) in the two groups were compared, and significant measurement was evaluated in respect of PFS. Result NLR ratio is the only measurement correlating with PFS (P < 0.05), with a median NLR of 3.2, and a range of 0.25- 43.30. The median of PFS was 68 months in the lower NLR group (NLR < 3.2), compared with 43 months in the higher NLR group (≥ 3.2) (P = 0.015). Conclu-sion Pre-operative NLR may be a biomarker to assess the PFS of early-stage cervical carcinoma, higher NLR indi-cates a worse prognosis.